Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Sabrina Wimmer

Biographic Data

ID7990173
NAMESabrina Wimmer
GIVEN NAMESSabrina
FAMILY NAMEWimmer
SIGNATUREWIMMER S
AFFILIATIONSManchester University NHS Foundation Trust
ORCID0000-0003-3040-7242
VERIFIEDYes
TOTAL WORKS2
TOTAL CITATIONS0
WORKS AS AUTHOR2
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2021
LATEST PUBLICATION YEAR2022
H-INDEX0
  • University patenting and licensing practices in the United Kingdom during the first year of the Covid-19 pandemic

    Open Access•Sarai Keestra, Florence Rodgers et al.•ARTICLE•Global Public Health•2022

    Universities' decisions during technology transfer may affect affordability, accessibility, and availability of COVID-19 health technologies downstream. We investigated measures taken by the top 35 publicly funded UK universities to ensure global equitable access to COVID-19 health technologies between January and end of October 2020. We sent Freedom Of Information (FOI) requests and analysed universities’ websites, to (i) assess institutional st…

  • Who funded the research behind the Oxford–AstraZeneca Covid-19 vaccine

    Open Access•Samuel Cross, Yeanuk Rho et al.•ARTICLE•BMJ Global Health•2021

    OBJECTIVES: The Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19, Vaxzevira or Covishield) builds on two decades of research and development (R&D) into chimpanzee adenovirus-vectored vaccine (ChAdOx) technology at the University of Oxford. This study aimed to approximate the funding for the R&D of ChAdOx and the Oxford-AstraZeneca vaccine and to assess the transparency of funding reporting mechanisms. METHODS: We conducted a scoping review an…

No prominent works on this page.

  • Who funded the research behind the Oxford–AstraZeneca Covid-19 vaccine

    Open Access•Samuel Cross, Yeanuk Rho et al.•ARTICLE•BMJ Global Health•2021

    OBJECTIVES: The Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19, Vaxzevira or Covishield) builds on two decades of research and development (R&D) into chimpanzee adenovirus-vectored vaccine (ChAdOx) technology at the University of Oxford. This study aimed to approximate the funding for the R&D of ChAdOx and the Oxford-AstraZeneca vaccine and to assess the transparency of funding reporting mechanisms. METHODS: We conducted a scoping review an…

  • University patenting and licensing practices in the United Kingdom during the first year of the Covid-19 pandemic

    Open Access•Sarai Keestra, Florence Rodgers et al.•ARTICLE•Global Public Health•2022

    Universities' decisions during technology transfer may affect affordability, accessibility, and availability of COVID-19 health technologies downstream. We investigated measures taken by the top 35 publicly funded UK universities to ensure global equitable access to COVID-19 health technologies between January and end of October 2020. We sent Freedom Of Information (FOI) requests and analysed universities’ websites, to (i) assess institutional st…

Medicine (2 works) · Political science (2 works) · 2019-20 coronavirus outbreak (1 work) · Best practice (1 work) · Business (1 work) · Coronavirus disease 2019 (COVID-19 (1 work) · Disease (1 work) · Economic growth (1 work) · Economics (1 work) · Emerging technologies (1 work)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae